Psilocybe cubensis

Traditional and historical use

Archaeological evidence places ceremonial psilocybin mushroom use by Mesoamerican indigenous peoples at least 3,000–3,500 years into the past, based on mushroom-shaped stone effigies from Guatemala and southern Mexico dating from approximately 1000 BCE to 900 CE.^[3] The Mazatec people of Oaxaca, Mexico are the best-documented practitioners, using psilocybin mushrooms — called teonanácatl (Nahuatl: "flesh of the gods") — in the Velada, a nocturnal healing ceremony guided by a curandera or curandero. An annotated bibliography spanning 49 scholarly works documents indigenous psilocybin practices across anthropology, archaeology, ethnolinguistics, and ethnomycology.^[9]

Western discovery and research

R. Gordon Wasson, an amateur mycologist and J.P. Morgan vice president, participated in a Mazatec Velada ceremony with the curandera María Sabina in 1955 and published his account in Life magazine in May 1957 — the first major Western public exposure to psilocybin mushrooms.^[10] Roger Heim collected and identified the specimens, and Albert Hofmann at Sandoz Laboratories isolated and characterized psilocybin and psilocin in 1958, naming both compounds after the Psilocybe genus.^[11]

Modern era

Psilocybin was classified as Schedule I under the U.S. Controlled Substances Act in 1970, and the 1971 UN Convention on Psychotropic Substances listed psilocybin and psilocin as Schedule I — though psilocybin mushrooms themselves were not explicitly named in the Convention text.^[12] Research effectively ceased for three decades until a 2006 double-blind study at Johns Hopkins demonstrated that psilocybin reliably occasioned mystical-type experiences, with 67% of volunteers rating the session among their five most personally meaningful life experiences.^[4]

Subsequent milestones include FDA Breakthrough Therapy designations for treatment-resistant depression (2018) and major depressive disorder (2019), Oregon's regulated psilocybin services framework (first centres opened 2023), Colorado's decriminalization of personal use (2022), and Australia's TGA rescheduling to Schedule 8 for authorised psychiatric prescribing.^[13]

Psilocybe cubensis (Earle) Singer belongs to the family Hymenogastraceae. First described as Stropharia cubensis by Franklin Sumner Earle in 1906 from Cuban specimens,^[14] the species was transferred to Psilocybe by Rolf Singer in 1949. Gastón Guzmán's 1983 monograph The Genus Psilocybe remains the authoritative taxonomic treatment, describing approximately 144 species at publication.^[15]

P. cubensis is a coprophilic, subtropical-to-tropical species found naturally across Central America, South America, Southeast Asia, and northern Australia, typically fruiting from cattle or horse dung in warm, humid pastures. It is the most widely cultivated psilocybin mushroom, owing to vigorous growth on simple substrates (brown rice flour, vermiculite, pasteurised grain) and tolerance of variable growing conditions.

The mature fruiting body has a convex to broadly umbonate cap, 2–8 cm in diameter, ranging from pale golden to caramel brown and often developing a darker centre. The stipe is 4–15 cm long, whitish, and bruises blue-green when damaged — a hallmark bluing reaction indicating psilocybin-containing tissue. The spore print is purplish-black to dark brown. The critical identification concern for wild foragers is distinguishing Psilocybe from the hepatotoxic Galerina marginata, which contains lethal amatoxins.^[16] The most reliable field-level discriminators are spore print colour (purplish-black for Psilocybe versus rusty-brown for Galerina) and the presence of the bluing reaction on damaged tissue.

Fruiting bodies are typically harvested just before or shortly after the veil breaks and dried for storage. Drying preserves alkaloid content for months to years. Fresh mushrooms contain approximately 90% water by weight, so 1 g dried material corresponds to roughly 10 g fresh.

The dominant psychoactive constituent of P. cubensis is psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), a tryptamine prodrug rapidly dephosphorylated in the body to psilocin (4-hydroxy-N,N-dimethyltryptamine) by alkaline phosphatases.^[17] Psilocin is the pharmacologically active molecule, acting primarily as a partial agonist at 5-HT₂A serotonin receptors.^[2] Typical dried P. cubensis fruiting bodies contain 0.5–1.0% psilocybin and 0.1–0.3% psilocin by dry weight, though concentrations vary widely across specimens.

The mushroom matrix delivers psilocybin alongside endogenous β-carboline alkaloids that function as MAO-A (MAO-A) inhibitors.^[18] Because MAO-A participates in psilocin degradation, these β-carbolines may extend psilocin's effective duration in whole-mushroom preparations relative to synthetic psilocybin. This "entourage" interaction is supported by preclinical evidence^[19] but has not been quantified in human pharmacokinetic studies.

Minor alkaloids identified in P. cubensis include baeocystin (norpsilocybin), norbaeocystin, and aeruginascin — structurally related tryptamines present at lower concentrations. Their individual contributions to the subjective experience remain poorly characterised, with existing data limited to in vitro studies and anecdotal reports.

Alkaloid content varies 2–4-fold across individual fruiting bodies even within a single cultivation batch.^[8] Factors influencing potency include substrate composition, growing conditions, harvest timing, and the specific cultivar or genetic lineage. This variability is the primary obstacle to dose standardisation when using uncharacterised mushroom material.

Psilocybin's oral bioavailability is approximately 52.7%, with psilocin reaching peak plasma concentration (tmax) at 1.8–4 hours and an half-life of 1.5–4 hours.^[20] Metabolism proceeds primarily via CYP2D6 and CYP3A4, with secondary MAO-A contribution.^[17]

Where it acts

Psilocin crosses the blood-brain barrier and binds 5-HT₂A receptors concentrated in pyramidal neurons of the prefrontal cortex — the primary mechanism underlying psychedelic effects.^[2] Additional engagement of 5-HT₁A receptors contributes to synaptic depression via enhanced GABAergic signalling,^[21] while direct activation of TrkB (BDNF) receptors may explain neuroplastic effects persisting well beyond acute drug activity.^[2]

What it changes

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psilocin loosens top-down cortical predictions, allowing greater bottom-up sensory influence and increasing entropy in brain signals.^[22] Precision fMRI tracking of individual brains found that a single 25 mg psilocybin dose disrupted functional connectivity more than threefold compared to methylphenidate, with the strongest effects in the default mode network. A persistent decrease in hippocampal-default mode network connectivity lasted three weeks post-session — hypothesised as a neuroanatomical correlate of psilocybin's pro-plasticity and therapeutic effects.^[23]

Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

In clinical trials, adverse events are frequent but predominantly transient and self-limiting. The largest Phase 2 trial (233 participants with treatment-resistant depression) reported adverse events in 77% of participants — most commonly headache, nausea, and dizziness.^[24] A Phase 2 RCT of 25 mg psilocybin for major depressive disorder found no serious treatment-emergent adverse events.^[25]

Cardiovascular effects are generally mild and transient, including modest increases in blood pressure and heart rate. Insufficient data exist on psilocybin safety in patients with established cardiovascular disease.^[26]

Standard workplace urine drug screens do not reliably detect psilocin, with approximately 1.3% cross-reactivity on amphetamine/methamphetamine assays.^[27][28] Confirmatory GC-MS or LC-MS/MS is required for definitive identification. Psilocin is detectable in urine for approximately 24–72 hours after ingestion.

Contaminant and adulterant risks: Wild-harvested mushrooms carry the primary danger of misidentification with hepatotoxic species, particularly Galerina marginata (amatoxin-containing), which can be fatal.^[16] Commercially obtained products sold as psilocybin may be adulterated with synthetic substances — NBOMe-series compounds have been detected in pressed tablets and powders. Ehrlich reagent testing produces a purple/violet reaction confirming indole presence but does not rule out all synthetic imposters; definitive identification requires GC-MS or LC-MS/MS.^[27]

Cultivated mushrooms are susceptible to mould contamination (Trichoderma spp., cobweb mould), implying potential mycotoxin exposure.safety citation needed No ISO/IEC-accredited lab testing programs or Certificate of Analysis requirements currently apply to psilocybin mushroom products in any jurisdiction with regulated access.

Persisting psychosis is rare but documented, primarily in individuals with personal or family history of psychotic disorders. This is the principal screening contraindication in all clinical research protocols.^[7]

Hallucinogen persisting perception disorder (HPPD) involves persistent visual disturbances — geometry, halos, trails, visual haze / noise — continuing after use ceases. Psilocybin and LSD are the most commonly reported precipitants.^[29] HPPD has been documented in adolescents^[30] and adults; precise prevalence estimates remain unavailable.

Psilocybin produces no physical dependence and no clinically recognised withdrawal syndrome.^[7][31] The DSM-5 does not include a hallucinogen withdrawal. A systematic review of psilocybin for substance use disorders found no addiction signals.^[32]

SSRIs: Long-term SSRI use is associated with blunted subjective psychedelic effects, likely via 5-HT₂A receptor downregulation. A post-hoc analysis found that antidepressant discontinuation prior to psilocybin did not significantly affect clinical outcomes in treatment-resistant depression.^[34] No serotonin syndrome cases from SSRI + psilocybin have been documented in the peer-reviewed literature.

Lithium: The lithium + psilocybin combination is flagged as potentially hazardous, with proposed mechanisms including serotonergic amplification and lithium's pro-convulsant effects.^[7] safety citation needed

Cannabis: Additive effects on anxiety and paranoia have been reported. Co-administration may intensify subjective effects. No specific pharmacokinetic interaction is documented.

CYP2D6 inhibitors: Drugs inhibiting CYP2D6 (fluoxetine, paroxetine, bupropion, quinidine) may prolong psilocin exposure by impairing its primary metabolic pathway.^[17]

Contraindications

Psilocybin and psilocin are Schedule I substances under the 1971 UN Convention on Psychotropic Substances, though psilocybin mushrooms themselves were not explicitly listed in the Convention text.^[12] This ambiguity has allowed several jurisdictions to permit whole-mushroom or truffle use while formally prohibiting the isolated compounds. The legal landscape is shifting rapidly: regulated therapeutic access now exists in Oregon, Australia, and (via exemption) Canada, while federal prohibition continues in the United States, the United Kingdom, and most of Europe.

The distinction between scheduled compounds (psilocybin, psilocin) and unscheduled biological material (mushrooms, truffles) under the 1971 UN Convention creates the legal space used by jurisdictions such as the Netherlands and Jamaica. National implementations vary in whether compound scheduling extends to the biological source organism or is restricted to isolated substances.